Zai Lab is a technology company.
Zai Lab has raised $188.0M across 4 funding rounds.
Zai Lab has raised $188.0M in total across 4 funding rounds.
Zai Lab is a global, commercial-stage biopharmaceutical company that discovers, develops, and commercializes transformative medicines—primarily in oncology, immunology, neuroscience and infectious disease—operating from China and the United States and running both internal R&D and partner programs[3][1].
High-Level Overview
Zai Lab builds and commercializes therapeutics (small molecules and biologics) through a hybrid model of internal discovery/development plus global partnerships; its pipeline targets oncology, autoimmune disorders, infectious diseases and neurological disorders and includes both in‑house candidates and partnered products that have reached commercial launch in China[3][1]. The company serves patients, clinicians, and health systems worldwide by addressing unmet medical needs (e.g., cancer and autoimmune disease) and by providing development and commercialization capabilities to partners seeking China and broader-market access[3][1]. Zai has demonstrated commercial momentum with multiple approved/Launched products in China and a broad late‑stage pipeline while scaling internal discovery (discovery sites in Shanghai and the San Francisco Bay Area) and manufacturing (small‑ and large‑molecule cGMP facilities completed 2017–2018)[5][1].
Origin Story
Zai Lab was founded in 2014 and is led (founder/CEO and chair noted publicly) as a company purpose‑built to be a global biopharma bridging China and Western markets[3][2]. The firm assembled experienced drug‑development, regulatory and commercial teams and pursued a two‑track strategy from early on: in‑house discovery and development plus strategic licensing/partnering with global biopharma companies; this approach produced early traction through partnerships (e.g., Amgen, GSK, Seagen, BMS and others) and progressing multiple programs into late‑stage development and regulatory filings[5][1]. Early pivotal moments include building internal GMP manufacturing capacity (2017–2018) and completing global clinical/regulatory programs that supported product approvals and launches in China[1][5].
Core Differentiators
Role in the Broader Tech/Biotech Landscape
Quick Take & Future Outlook
Zai Lab’s near‑term trajectory depends on clinical readouts and regulatory progress for its late‑stage internal assets and on continued execution of partnerships and China commercial launches; successful global registrational studies and additional approvals would materially increase its influence and commercial scale[5][1]. Trends that will shape Zai’s future include tighter competition for oncology/autoimmune assets, evolving China regulatory policy and pricing/reimbursement dynamics, and continued emphasis on biologics/ADC and bispecific modalities—areas in which Zai is investing[3][1]. If Zai continues to deliver clinical differentiation and to industrialize development and manufacturing, it can strengthen its role as a bridge between Western biotech innovation and Chinese commercial markets—fulfilling its founding mission to bring transformative medicines from lab to patients globally[3][1].
Zai Lab has raised $188.0M in total across 4 funding rounds.
Zai Lab's investors include Qiming Venture Partners.
Zai Lab has raised $188.0M across 4 funding rounds. Most recently, it raised $30.0M Series C in June 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2017 | $30.0M Series C | Qiming Venture Partners | |
| Jan 1, 2016 | $110.0M Series B | Qiming Venture Partners | |
| Apr 1, 2015 | $18.0M Series A | Qiming Venture Partners | |
| Aug 1, 2014 | $30.0M Series A | Qiming Venture Partners |